Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Pfizer to codevelop Myovant cancer drug
by Ryan Cross
January 2, 2021
| A version of this story appeared in
Volume 99, Issue 1
Pfizer will pay $650 million up front and up to $4.2 billion in milestone payments to Myovant Sciences to jointly develop relugolix, an oral gonadotropin-releasing hormone receptor antagonist. The drug, which reduces testicular testosterone, was recently approved in the US for treating advanced prostate cancer. Relugolix also reduces ovarian estradiol. A tablet containing relugolix and a small amount of estradiol and norethindrone acetate is under regulatory review for treating uterine fibroids and is in clinical studies for treating endometriosis.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X